



(51) International Patent Classification:

C07D 401/12 (2006.01) **A61P 3/04** (2006.01)
A61K 31/415 (2006.01)

(21) International Application Number:

PCT/US2011/054841

(22) International Filing Date:

5 October 2011 (05.10.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/390,888 7 October 2010 (07.10.2010) US

(71) Applicant (for all designated States except US): **NO-VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SUTTON, Paul, Allen** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **GIRGIS, Michael, J.** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **LIANG, Jessica** [CN/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **PRASHAD, Mahavir** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **VILLHAUER, Edwin, Bernard** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US).

(74) Agent: **MATOVCIK, Lisa**; Novartis Pharmaceuticals Corporation, Patent Department, One Health Plaza, East Hanover, NJ 07936-1080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: NEW CRYSTALLINE FORMS OF THE SODIUM SALT OF (4- {4- [5- (6 - TRIFLUOROMETHYL - PYRIDIN- 3 - YLAMINO) - PYRIDIN- 2 -YL] -PHENYL} - CYCLOHEXYL) -ACETIC ACID

(57) Abstract: The present invention relates to novel crystalline forms of (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, sodium and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. It also relates processes for making such novel crystalline forms.

